Abstract:Abstract Recent reports revealed that endothelial progenitor cells (EPCs) isolated from bone marrow, cord blood or embryos have been experimentally utilized to deliver therapeutic agents for cancer treatment. Their potential in cancer therapy highlights the need for a consistent and renewable source of endothelial cells for clinical applications. Moreover, one of the most critical issues for ensuring success of endothelial therapy is the development of technologies for non-invasive monitoring of the distribution of transplanted cells and kinetic of tumor progression or regression. We generated human embryonic stem cell-derived endothelial cells (hESC-ECs) from H9 cell line. The hESC-ECs resemble adult endothelial cells HUVEC in endothelial markers and angiogenesis potential. In vitro study revealed the paracrine effects of hESC-ECs on tumor cells using conditioned medium (EC-CM). After treated with EC-CM, human breast cancer cells MDA-MB-231 proliferated slower and exhibited a higher apoptosis rate in low-serum condition, and the migration ability was impaired. Furthermore, we introduced a multitude of non-invasive, quantitative, functional imaging techniques with reporter gene methods to probe breast cancer model processes, and to track the hESC-ECs for targeting therapy in vivo by firefly luciferase (Fluc)/renilla luciferase (Rluc) imaging. We transduced hESC-ECs with triple fusion (TF) reporter gene containing the herpes simplex virus truncated thymidine kinase (HSV-ttk), renilla luciferase (Rluc) and RFP (RL-RFP-HSV-ttk). The NOD/SCID mice breast cancer metastasis model was established by tail vein injection of 1.5×106 MDA-MB-231 cells, which carry a reporter system encoding the gene of Fluc and GFP. Bioluminescence imaging (BLI) revealed that hESC-ECs can be sequenced in tumor sites for more than 72 hours. When given pro-drug ganciclovir (GCV), targeting HSV-ttk gene, the MDA-MB-231 tumor was inhibited by the indication of Fluc imaging. And immunofluorescence staining also confirmed that hESC-EC can exclusively home to tumor lesions instead of normal lung tissue. Taken together, our results revealed that hESC-ECs can specifically target tumor sites and kill nearby tumor cells by bystander effect when GCV is given. These finds suggest that hESC-ECs are attractive targeting vehicles for cancer therapy, and molecular imaging in small animals is an invaluable part of cancer diagnosis, prediction of tumor response to available therapies and monitoring response to therapy as well as developing drugs prior to clinical translation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 415. doi:1538-7445.AM2012-415

Anti‐Tumor Effect of Embryonic Stem Cell Derived Exosomes in Triple Negative Breast Cancer: Potential Role of TCF7‐E‐Cadherin and VEGF

The Antitumor Effect of Gene-Engineered Exosomes in the Treatment of Brain Metastasis of Breast Cancer.

TFEB and TFE3 Depletion Increases Cancer Stem Cell Characteristics and EMT in Triple‐Negative Breast Cancer

The Triple Adipose-Derived Stem Cell Exosome Technology as a Potential Tool for Treating Triple-Negative Breast Cancer

Exosomes from Adipose-Tissue-Derived Stem Cells Induce Proapoptotic Gene Expression in Breast Tumor Cell Line

"Triple-Punch" Strategy Exosome-Mimetic Nanovesicles for Triple Negative Breast Cancer Therapy.

Adipose-derived stem cell exosomes promote tumor characterization and immunosuppressive microenvironment in breast cancer

The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth

Embryonic Stem Cell Preconditioned Microenvironment Suppresses Tumorigenic Properties in Breast Cancer

Proteomic Landscape of Exosomes Reveals the Functional Contributions of CD151 in Triple-Negative Breast Cancer

Tweaking EMT and MDR dynamics to constrain triple-negative breast cancer invasiveness by EGFR and Wnt/β-catenin signaling regulation

Exosomes: Small Vesicles with Important Roles in the Development, Metastasis and Treatment of Breast Cancer

Exosome-delivered Micrornas Confer Adriamycin-Resistance Through Modulating the Immune and Metabolism-Related Gene PTEN in HER2-negative Breast Cancer.

Single-cell transcriptomics reveals the intra-tumoral heterogeneity and SQSTM1/P62 and Wnt/β-catenin mediated epithelial to mesenchymal transition and stemness of triple-negative breast cancer

Autocrine Motility Factor and Its Peptide Derivative Inhibit Triple-Negative Breast Cancer by Regulating Wound Repair, Survival, and Drug Efflux

Extracellular Vesicles in Triple–Negative Breast Cancer: Immune Regulation, Biomarkers, and Immunotherapeutic Potential

Human Embryonic Stem Cell-Derived Endothelial Cells As Cellular Delivery Vehicles for Targeting Therapy of Metastatic Breast Cancer

Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3,3′-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer

Engineered extracellular vesicles for combinatorial TNBC therapy: SR-SIM-guided design achieves substantial drug dosage reduction

Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer.

Innovative Therapeutic Delivery of Metastasis-Associated in Colon Cancer 1-Suppressing miRNA Using High Transmembrane 4 L6 Family Member 5-Targeting Exosomes in Colorectal Cancer Mouse Models